Patient-reported outcomes in the phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis

Authors
Category Primary study
ConferenceMultiple Sclerosis
Year 2017
This article has no abstract
Epistemonikos ID: d02d28b75136e78f1acdf77327517bbb8ea80ba9
First added on: Apr 29, 2026